Watch MBRX. Know when insiders buy.
One email the day a filing lands. Free.
MBRX
Moleculin Biotech, Inc.
0.77
−0.01 −0.90%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $15.1MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$30.3MNET CASH —52W 0.38 – 13.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$7.6M | −$7.6M | — | -1.40 | −$6.7M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $0 | — | — | −$7.9M | −$12.8M | — | -3.54 | −$6.1M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$7.5M | $15.6M | — | -26.06 | −$5.4M | $0 | −$5.4M | Mar 18 |
| Q3 2025 · Sep 30 | $0 | — | — | −$5.9M | −$25.4M | — | -0.68 | −$7.2M | $0 | −$7.2M | Nov 13 |
| Q2 2025 · Jun 30 | $0 | — | — | −$5.7M | −$17.8M | — | -28.68 | −$5.6M | $0 | −$5.6M | Aug 13 |
| Q1 2025 · Mar 31 | $0 | — | — | −$5.9M | −$5.9M | — | -15.80 | −$4.6M | $0 | −$4.6M | Aug 13 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$6.6M | −$6.6M | — | -182.45 | −$5.1M | $0 | −$5.1M | Mar 18 |
| Q3 2024 · Sep 30 | $0 | — | — | −$7.1M | −$7M | — | -1.89 | −$6.1M | $0 | −$6.1M | Nov 13 |
| Q2 2024 · Jun 30 | $0 | — | — | −$6.2M | −$6M | — | -2.37 | −$5.9M | $13K | −$6M | Nov 13 |
| Q1 2024 · Mar 31 | $0 | — | — | −$6.7M | −$6.4M | — | -2.61 | −$6.7M | $0 | −$6.7M | Nov 13 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$8.9M | −$10.3M | — | -5.13 | −$4.9M | $81K | −$5M | Mar 21 |
| Q3 2023 · Sep 30 | $0 | — | — | −$5.9M | −$5.6M | — | -2.82 | −$7.6M | $28K | −$7.6M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$25.1M | −$33.6M | — | -28.42 | −$22.7M | $0 | −$22.7M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$26.6M | −$26M | — | -189.14 | −$23.9M | $13K | −$23.9M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$29.6M | −$29.8M | — | -15.07 | −$23.6M | $124K | −$23.7M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$30.6M | −$29M | — | -15.22 | −$27.6M | $67K | −$27.7M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$23M | −$15.9M | — | -0.59 | −$19M | $19K | −$19M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$19.7M | −$17.4M | — | -1.76 | −$17.8M | $376K | −$18.1M | — | — |
Every number comes from Moleculin Biotech, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.